|
1
|
Erickson Lori A: Papillary thyroid
carcinoma. Atlas of Endocrine Pathology. 1–50. 2014. View Article : Google Scholar
|
|
2
|
Rahbari R, Zhang L and Kebebew E: Thyroid
cancer gender disparity. Future Oncol. 6:1771–1779. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sipos JA and Mazzaferri EL: Thyroid cancer
epidemiology and prognostic variables. Clin Oncol (R Coll Radiol).
22:395–404. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Caron NR and Clark OH: Papillary thyroid
cancer. Curr Treat Options Oncol. 7:309–319. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xing M, Westra WH, Tufano RP, Cohen Y,
Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, et
al: BRAF mutation predicts a poorer clinical prognosis for
papillary thyroid cancer. J Clin Endocrinol Metab. 90:6373–6379.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nikiforov YE: Molecular diagnostics of
thyroid tumors. Arch Pathol Lab Med. 135:569–577. 2011.PubMed/NCBI
|
|
7
|
Pelizzo MR, Dobrinja C, Casal Ide E, Zane
M, Lora O, Toniato A, Mian C, Barollo S, Izuzquiza M, Guerrini J,
et al: The role of BRAF(V600E) mutation as poor prognostic factor
for the outcome of patients with intrathyroid papillary thyroid
carcinoma. Biomed Pharmacother. 68:413–417. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Afkhami M, Karunamurthy A, Chiosea S,
Nikiforova MN, Seethala R, Nikiforov YE and Coyne C:
Histopathologic and clinical characterization of thyroid tumors
carrying the BRAF K601E mutation. Thyroid. 26:242–247. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jara SM, Bhatnagar R, Guan H, Gocke CD,
Ali SZ and Tufano RP: Utility of BRAF mutation detection in
fine-needle aspiration biopsy samples read as ‘suspicious for
papillary thyroid carcinoma’. Head Neck. 37:1788–1793. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Macerola E, Loggini B, Giannini R,
Garavello G, Giordano M, Proietti A, Niccoli C, Basolo F and
Fontanini G: Coexistence of TERT promoter and BRAF mutations in
cutaneous melanoma is associated with more clinicopathological
features of aggressiveness. Virchows Arch. 467:177–184. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xing M: Clinical utility of RAS mutations
in thyroid cancer: A blurred picture now emerging clearer. BMC Med.
14:122016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vinagre J, Almeida A, Pópulo H, Batista R,
Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, et al:
Frequency of TERT promoter mutations in human cancers. Nat Commun.
4:21852013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Muzza M, Colombo C, Rossi S, Tosi D,
Cirello V, Perrino M, De Leo S, Magnani E, Pignatti E, Vigo B, et
al: Telomerase in differentiated thyroid cancer: Promoter
mutations, expression and localization. Mol Cell Endocrinol.
399:288–295. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Park CK, Lee SH, Kim JY, Kim JE, Kim TM,
Lee ST, Choi SH, Park SH and Kim IH: Expression level of hTERT is
regulated by somatic mutation and common single nucleotide
polymorphism at promoter region in glioblastoma. Oncotarget.
5:3399–3407. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu X, Bishop J, Shan Y, Pai S, Liu D,
Murugan AK, Sun H, El-Naggar AK and Xing M: Highly prevalent TERT
promoter mutations in aggressive thyroid cancers. Endocr Relat
Cancer. 20:603–610. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Horn S, Figl A, Rachakonda PS, Fischer C,
Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, et al:
TERT promoter mutations in familial and sporadic melanoma. Science.
339:959–961. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yarchoan M, LiVolsi VA and Brose MS: BRAF
mutation and thyroid cancer recurrence. J Clin Oncol. 33:7–8. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gandolfi G, Ragazzi M, Frasoldati A, Piana
S, Ciarocchi A and Sancisi V: TERT promoter mutations are
associated with distant metastases in papillary thyroid carcinoma.
Eur J Endocrinol. 172:403–413. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Esserman LJ, Thompson IM Jr and Reid B:
Overdiagnosis and overtreatment in cancer: An opportunity for
improvement. JAMA. 310:797–798. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Torregrossa L, Viola D, Sensi E, Giordano
M, Piaggi P, Romei C, Materazzi G, Miccoli P, Elisei R and Basolo
F: Papillary thyroid carcinoma with rare exon 15 BRAF mutation has
indolent behavior: A single-institution experience. J Clin
Endocrinol Metab. 101:4413–4420. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shi X, Liu R, Qu S, Zhu G, Bishop J, Liu
X, Sun H, Shan Z, Wang E, Luo Y, et al: Association of TERT
promoter mutation 1,295,228 C>T with BRAF V600E mutation, older
patient age and distant metastasis in anaplastic thyroid cancer. J
Clin Endocrinol Metab. 100:E632–E637. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xing M, Liu R, Liu X, Murugan AK, Zhu G,
Zeiger MA, Pai S and Bishop J: BRAF V600E and TERT promoter
mutations cooperatively identify the most aggressive papillary
thyroid cancer with highest recurrence. J Clin Oncol. 32:2718–2726.
2014. View Article : Google Scholar : PubMed/NCBI
|
